These results will help clarify the potential mechanism of BBB destruction after cerebral ischemia at the molecular level, and CAY-10444, a specific inhibitor of S1PR3, is expected to become a clinical drug for cerebral infarction, providing guidance for the pathogenesis, diagnosis, and treatment of cerebral infarction. Here, S1PR3 is linked to brain infarction.